Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Net Income (2016 - 2025)

Historic Net Income for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $40000.0.

  • NovaBay Pharmaceuticals' Net Income fell 9376.95% to $40000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$925000.0, marking a year-over-year increase of 5934.07%. This contributed to the annual value of -$124000.0 for FY2024, which is 9681.97% up from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Net Income is $40000.0, which was down 9376.95% from -$965000.0 recorded in Q4 2024.
  • In the past 5 years, NovaBay Pharmaceuticals' Net Income registered a high of $642000.0 during Q3 2024, and its lowest value of -$8.2 million during Q4 2022.
  • Moreover, its 5-year median value for Net Income was -$399000.0 (2023), whereas its average is -$1.3 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 509367.09% in 2022, then surged by 25891.09% in 2024.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Net Income stood at -$158000.0 in 2021, then crashed by 5093.67% to -$8.2 million in 2022, then surged by 65.96% to -$2.8 million in 2023, then skyrocketed by 65.45% to -$965000.0 in 2024, then soared by 104.15% to $40000.0 in 2025.
  • Its Net Income stands at $40000.0 for Q3 2025, versus -$965000.0 for Q4 2024 and $642000.0 for Q3 2024.